Abstract 173P
Background
Breast cancer (BC) presents challenges in predicting disease progression despite advancements in treatment and monitoring. Circulating tumor cells (CTCs) were initially seen as promising for prognosis via liquid biopsy, but complexities in their investigation have emerged over the past 15 years. Variability in isolation methods and the absence of universal CTC markers hinder standardization and comparison of research findings. In the present study we focused on CD24 which shows potential as a prognostic marker of BC. This study aims to elucidate the prognostic significance of CD24+ circulating cells in peripheral blood of BC patients.
Methods
The study included 57 patients with invasive breast carcinoma of no special type (IC NST) T1-4N0-3M0-1. Circulating cell phenotypes assessment was carried out by flow cytometry (Novocyte 3000, ACEA Biosciences, USA) using monoclonal antibody cocktail.
Results
In our investigation we utilized epithelial markers EpCAM and cytokeratin 7/8 to assess CTCs, including both metastatic and non-metastatic BC patients. Surprisingly, these markers were insufficient in identifying CTC populations indicative of distant metastasis in BC. However, we made the intriguing discovery of CD45-CD24+ circulating cells lacking epithelial markers EpCAM and CK7/8 associated with distant metastasis. Increased level of CD45-EpCAM-CK7/8-CD24+N-cadherin- circulating cells were observed among patients with established metastases and those who developed metastatic lesions during subsequent monitoring. Furthermore, exceeding a threshold of 218.3 cells per milliliter of peripheral blood before treatment predicted a 12-fold increase in metastatic risk and a 3-fold reduction in DMFS over a 90-month period. The unveiled cell population could originate with equal probability from epithelial cells that have undergone EMT or from immature cells from bone marrow. However, it should be noted that these CCs do not align with any recognized stages of monocyte or neutrophil maturation.
Conclusions
The count of CD45-EpCAM-CK7/8-CD24+N-cadherin- CCs was associated with distant metastasis, as their numbers were elevated in peripheral blood of patients with metastases during the follow-up period.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The study was supported by the Russian Science Foundation (grant #23-15-00135).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
122P - Practice patterns and treatment outcomes of molecular tumour board (MTB)-based personalized cancer therapies: A single-center experience
Presenter: Florian Moik
Session: Poster session 08
123P - Pan-cancer homologous recombination deficiency (HRD) evaluation in patients enrolled in a routine molecular screening program
Presenter: Paula Romero-Lozano
Session: Poster session 08
124P - Incidence of activating frameshift and nonsense mutations in clinically actionable oncogenes
Presenter: Sjors Kas
Session: Poster session 08
125P - Comparison of microarray and next-generation sequencing-based approaches for detection of homologous recombination deficiency
Presenter: Caleb Kidwell
Session: Poster session 08
126P - Genomic landscape and prognostic impact of HER2 low-expressing tumors
Presenter: Aditya Shreenivas
Session: Poster session 08
127P - Clinical utility of circulating tumor DNA (ctDNA) next generation sequencing (NGS) to inform treatment decisions for patients (pts) with advanced solid tumors
Presenter: Diego Gomez Puerto
Session: Poster session 08
128P - Whole blood transcriptomics identifies transcriptional patterns linked to outcomes in patients receiving immune checkpoint inhibitors
Presenter: Sara Hone Lopez
Session: Poster session 08
129P - Integrating large data to unveil vulnerabilities for patients with hot tumors resistant to checkpoint inhibition
Presenter: Anlin Li
Session: Poster session 08
130P - Ipilimumab plus nivolumab (Ipi+Nivo) in patients with tumors harboring high tumor mutational burden or load (TMB/TML-H): Results from the Drug Rediscovery Protocol (DRUP)
Presenter: Soemeya Haj Mohammad
Session: Poster session 08
131P - Systemic immune-inflammation index and overall survival with checkpoint inhibitors
Presenter: Oliver Kennedy
Session: Poster session 08